Robot | Path | Permission |
GoogleBot | / | ✔ |
BingBot | / | ✔ |
BaiduSpider | / | ✔ |
YandexBot | / | ✔ |
Title | aTen Therapeutics An innovative biotechnology |
Description | Recent Home Overview Pipeline News Contact Recent News August 2022 August 2022 aTen Therapeutics awarded £282k Innovate UK grant to develop new breast cancer tre |
Keywords | N/A |
WebSite | atentherapeutics.com |
Host IP | 160.153.129.206 |
Location | United States |
Site | Rank |
US$302,445
Last updated: 2023-05-17 14:33:25
atentherapeutics.com has Semrush global rank of 34,995,817. atentherapeutics.com has an estimated worth of US$ 302,445, based on its estimated Ads revenue. atentherapeutics.com receives approximately 34,898 unique visitors each day. Its web server is located in United States, with IP address 160.153.129.206. According to SiteAdvisor, atentherapeutics.com is safe to visit. |
Purchase/Sale Value | US$302,445 |
Daily Ads Revenue | US$280 |
Monthly Ads Revenue | US$8,376 |
Yearly Ads Revenue | US$100,505 |
Daily Unique Visitors | 2,327 |
Note: All traffic and earnings values are estimates. |
Host | Type | TTL | Data |
atentherapeutics.com. | A | 10800 | IP: 160.153.129.206 |
atentherapeutics.com. | NS | 3600 | NS Record: ns70.domaincontrol.com. |
atentherapeutics.com. | NS | 3600 | NS Record: ns69.domaincontrol.com. |
atentherapeutics.com. | MX | 3600 | MX Record: 0 atentherapeutics-com.mail.protection.outlook.com. |
atentherapeutics.com. | TXT | 3600 | TXT Record: v=spf1 include:spf.protection.outlook.com -all |
Home Overview Pipeline News Contact Recent News August 2022 August 2022 aTen Therapeutics awarded £282k Innovate UK grant to develop new breast cancer treatment. March 2020 aTen Therapeutics relocates to new offices at 1 Lochrin Square, Fountainbridge, Edinburgh EH3 9QA. August 2019 Ian Abercrombie appointed Chief Executive Officer at aTen Therapeutics. aTen Therapeutics An innovative biotechnology company based in Edinburgh, Scotland We are developing novel therapeutic antibodies to target a fundamental control pathway associated with cancer and several other major diseases. Our technology has great potential to provide powerful new treatment options to extend and improve lives. TENSINUMAB (ATN-E11) Our lead candidate - a novel therapeutic human antibody that significantly inhibits tumour growth and prolongs survival in experimental models of cancer. info@atentherapeutics.com © aTen Therapeutics 2022. All rights reserved home overview product terms of use news contact |
HTTP/1.1 302 Found Date: Sat, 02 Apr 2022 09:03:07 GMT Server: Apache Location: https://www.atentherapeutics.com/ Content-Type: text/html; charset=iso-8859-1 HTTP/2 200 last-modified: Thu, 23 Apr 2020 16:20:26 GMT etag: "8a80094-f6b-5a3f7a0592680" accept-ranges: bytes content-length: 3947 vary: Accept-Encoding content-type: text/html date: Sat, 02 Apr 2022 09:03:07 GMT server: Apache |
Domain Name: ATENTHERAPEUTICS.COM Registry Domain ID: 2027924241_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2018-10-31T10:58:02Z Creation Date: 2016-05-13T15:51:20Z Registry Expiry Date: 2022-05-13T15:51:20Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS69.DOMAINCONTROL.COM Name Server: NS70.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2022-04-02T09:33:26Z <<< |